Adlai Nortye Ltd.
AN4035
CEACAM5 pan- RAS(ON)i ADC CEACAM5- enriched RAS- addicted solid tumors
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for AN4035 in CEACAM5 pan- RAS(ON)i ADC CEACAM5- enriched RAS- addicted solid tumors are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“Clinical update in H2 2026”